New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For TSM;ATHN;MPEL;RHHBY;DST;MCD;SYT;AKR;AET From The Last 14 Days
Check below for free stories on TSM;ATHN;MPEL;RHHBY;DST;MCD;SYT;AKR;AET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 18, 2014
07:20 EDTTSMLG Display added to Asia Focus List, TSMC removed at JPMorgan
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
16:12 EDTATHNathenahealth trades up after earnings, levels to watch
Subscribe for More Information
16:09 EDTATHNathenahealth sees FY14 EPS 98c -$1.10, consensus $1.04
Sees FY14 revenue $725M -$755M, consensus $741.02M.
16:06 EDTATHNathenahealth reports Q2 EPS 32c, consensus 22c
Subscribe for More Information
15:26 EDTATHNNotable companies reporting after market close
Subscribe for More Information
14:40 EDTATHNathenahealth July 129 straddle priced for 8.7% move into Q2
Subscribe for More Information
14:30 EDTTSMFujitsu to exit chip making, sell plants to ON Semi, United Micro, Nikkei says
Subscribe for More Information
06:43 EDTTSMTSMC expects to lose out to competitors in 14/16nm segment, DigiTimes says
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
10:48 EDTTSMTSMC falls, levels to watch
Subscribe for More Information
10:00 EDTTSMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTSYTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:08 EDTTSMTSMC downgraded to Negative from Neutral at Susquehanna
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
06:18 EDTTSMTSMC volatility increases as shares trade near 14-year high
Subscribe for More Information
05:49 EDTTSMStocks with implied volatility movement; SDS TSM
Subscribe for More Information
05:33 EDTSYTSyngenta upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
July 15, 2014
07:29 EDTTSMASML Q2 results could miss expectations, says RBC Capital
Subscribe for More Information
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use